The evolving landscape of biomarkers for systemic therapy in advanced hepatocellular carcinoma

Xinyu Guo(National Engineering Research Center for Information Technology in Agriculture), Jiansong Ji(Wenzhou Medical University), Shuang Liu(Lishui Central Hospital), Lingyi Zhu(Zhejiang Chinese Medical University), Lingling Zhou(Chinese Academy of Sciences), Shiji Fang(Wenzhou Medical University), Liyun Zheng(Nanchang University), Fazong Wu(Wenzhou Medical University), Zhongwei Zhao(Central South University), Minjiang Chen(Chinese Academy of Medical Sciences & Peking Union Medical College)
Biomarker Research
April 12, 2025
10.1186/s40364-025-00774-2
Cited by 11

Related Papers

The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma
|Cell Communication and Signaling|2020|232
Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival
|Scientific Reports|2016|143
CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway
|Journal of Experimental & Clinical Cancer Research|2020|107
Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study
|Journal of Hepatology|2021|101
Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study
|Frontiers in Molecular Biosciences|2021|90